Endometrial Cancer Trial, Recruiting NCT05544084 Sponsor: University of Illinois at Chicago Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05544084
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

All participants (Samples a, b, and c):

  • People who are citizens of Senegal aged between 25 and 69 years old
  • People who are willing to take part in survey questions

Sample a (Advisory and Regional Team Members) — additional criteria:

  • People who have been invited to be a member of the study's National Advisory Board or Regional Implementation Resource Teams
  • People who are able to read and write in French

Sample b (Health Workers) — additional criteria:

  • People who are employed by the government at a participating health facility, including patient navigators, nurses, midwives who treat and educate patients, or community health workers (including Bajenu Gox — women's health educators) working at a facility or in the community

Sample c (Community Members) — additional criteria:

  • Women who are living with a male partner who also agrees to take part in the study, and who are eligible to seek cervical cancer prevention services at a designated health facility in Senegal
  • Men who are living in a household with at least one woman who is eligible to seek cervical cancer prevention services at a designated health facility in Senegal

Who may not be able to join:

  • The trial does not list any additional reasons that would prevent someone from joining beyond not meeting the criteria listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jon A Dykens, MD, MPH, University of Illinois at Chicago

Phone: 573-355-0452

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
30 March 2027

Where this trial is recruiting

Senegal

Primary endpoints

Change in the number of women screened for the first time, age stratified uptake through self-report questionnaire and confirmed through record review

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov